Release initial directional data from the IGNYTE anti-PD-1 failed melanoma cohort
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- 7 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to release initial directional data from this cohort in late 2022.”
What we found
Evidence strength A What the grades mean
Replimune announced initial data from IGNYTE anti-PD-1 failed melanoma cohort on December 7, 2022, within the late 2022 deadline.
-
A SEC Filing - Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort
“Woburn, MA, December 7, 2022– Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous m” ✓ confirmed on the page
-
B Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
“December 7, 2022 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma coh”
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Release
- Deliverable
- IGNYTE anti-PD-1 failed melanoma cohort data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002658 · Corrections policy